Close Menu

NEW YORK (GenomeWeb) – Children with a certain brain tumor subtype may benefit from the addition of bevacizumab to their treatment regimens, according to a new study.

A team led by researchers from the Institute of Cancer Research, London used data from the HERBY phase 2 trial — which analyzed how well children with non-brainstem high-grade glioma fared when bevacizumab (sold as Avastin in the US) was added to their treatment regimen — found that patients whose tumors had mutations within genes in the MAPK network appeared to benefit from the added treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.